Physician profile
Daniel A Eckstein
NPI 1366704843
$8,784.28
in general payments reported to CMS, 2019-2025
41 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,739 · 2020: $2,158 · 2021: $2,473 · 2022: $1,526 · 2023: $642 · 2024: $137 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $888.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,281.41 | 2019-2023 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $685.31 | 2020-2024 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $646.18 | 2019-2025 | Breztri |
| Janssen Pharmaceuticals, INC | $609.65 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $600.15 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $504.43 | 2019-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $474.37 | 2019-2022 | |
| Pfizer INC. | $461.83 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $447.32 | 2019-2023 | |
| Abbvie INC. | $409.39 | 2021-2024 | Vraylar |
| Biohaven Pharmaceuticals, INC. | $289.31 | 2021 | |
| Sanofi-Aventis U.S. LLC | $266.81 | 2019-2023 | |
| Daiichi Sankyo INC. | $240.99 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $224.95 | 2020-2022 | |
| Allergan, INC. | $184.03 | 2019-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Eckstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.